Targeting RET-rearranged non-small-cell lung cancer: future prospects

Non-small-cell lung cancer (NSCLC) patients with mutated or rearranged oncogene drivers can be treated with upfront selective inhibitors achieving higher response rates and longer survival than chemotherapy. The RET gene can undergo chromosomal rearrangements in 1%–2% of all NSCLC patients, involvin...

Descripción completa

Detalles Bibliográficos
Autores principales: Bronte, Giuseppe, Ulivi, Paola, Verlicchi, Alberto, Cravero, Paola, Delmonte, Angelo, Crinò, Lucio
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2019
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6433115/
https://www.ncbi.nlm.nih.gov/pubmed/30962732
http://dx.doi.org/10.2147/LCTT.S192830

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6433115/
https://www.ncbi.nlm.nih.gov/pubmed/30962732
http://dx.doi.org/10.2147/LCTT.S192830

Ejemplares similares